Mallat A - Search Results

1

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.

Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C, Pawlotsky JM. Hézode C, et al. Among authors: mallat a. Hepatology. 2016 Jun;63(6):1809-16. doi: 10.1002/hep.28491. Epub 2016 Mar 10. Hepatology. 2016. PMID: 26853230 Clinical Trial.

2

Inhibition of gastric alcohol dehydrogenase activity by histamine H2-receptor antagonists has no influence on the pharmacokinetics of ethanol after a moderate dose.

Mallat A, Roudot-Thoraval F, Bergmann JF, Trout H, Simonneau G, Dutreuil C, Blanc LE, Dhumeaux D, Delchier JC. Mallat A, et al. Br J Clin Pharmacol. 1994 Feb;37(2):208-11. doi: 10.1111/j.1365-2125.1994.tb04263.x. Br J Clin Pharmacol. 1994. PMID: 7910473 Free PMC article. Clinical Trial.

3

Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.

Pawlotsky JM, Darthuy F, Rémiré J, Pellet C, Udin L, Stuyver L, Roudot-Thoraval F, Duvoux C, Douvin C, Mallat A, et al. Pawlotsky JM, et al. Among authors: mallat a. J Med Virol. 1995 Nov;47(3):285-91. doi: 10.1002/jmv.1890470316. J Med Virol. 1995. PMID: 8551282

4

Acute fatal hepatitis related to sertraline.

Fartoux-Heymann L, Hézode C, Zafrani ES, Dhumeaux D, Mallat A. Fartoux-Heymann L, et al. Among authors: mallat a. J Hepatol. 2001 Nov;35(5):683-4. doi: 10.1016/s0168-8278(01)00159-3. J Hepatol. 2001. PMID: 11690719 No abstract available.

5

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.

Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D. Duvoux C, et al. Among authors: mallat a. Hepatology. 2002 Aug;36(2):374-80. doi: 10.1053/jhep.2002.34343. Hepatology. 2002. PMID: 12143045 Clinical Trial.

6

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Hézode C, et al. Among authors: mallat a. Hepatology. 2005 Jul;42(1):63-71. doi: 10.1002/hep.20733. Hepatology. 2005. PMID: 15892090

7

[Endocannabinoids: therapeutic perspectives in chronic liver diseases].

Lotersztajn S, Teixeira-Clerc F, Hezode C, Tran van Nhieu J, Deveaux V, Mallat A. Lotersztajn S, et al. Among authors: mallat a. Gastroenterol Clin Biol. 2007 Mar;31(3):255-8. doi: 10.1016/s0399-8320(07)89369-9. Gastroenterol Clin Biol. 2007. PMID: 17396081 Free article. French. No abstract available.

8

[The endocannabinoid system as a novel target for the treatment of liver fibrosis].

Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Hezode C, Mallat A, Lotersztajn S. Teixeira-Clerc F, et al. Among authors: mallat a. Pathol Biol (Paris). 2008 Feb;56(1):36-8. doi: 10.1016/j.patbio.2007.01.001. Epub 2007 Apr 6. Pathol Biol (Paris). 2008. PMID: 17412522 Review. French.

9

Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A. Hézode C, et al. Among authors: mallat a. Gastroenterology. 2008 Feb;134(2):432-9. doi: 10.1053/j.gastro.2007.11.039. Epub 2007 Nov 28. Gastroenterology. 2008. PMID: 18242211

10

Environmental factors as disease accelerators during chronic hepatitis C.

Mallat A, Hezode C, Lotersztajn S. Mallat A, et al. J Hepatol. 2008 Apr;48(4):657-65. doi: 10.1016/j.jhep.2008.01.004. Epub 2008 Jan 28. J Hepatol. 2008. PMID: 18279998 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169 results

Search Page